ReviewNeurodegenerative disease management2025
A drug evaluation narrative review of cladribine as a treatment for multiple sclerosis.
Review in Neurodegenerative disease management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Neurovascular Niche: A Gathering Venue for Neuroinflammation and Remyelination in Multiple Sclerosis.Acta physiologica (Oxford, England) · 2026Review
- Cladribine treatment in chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: two case reports.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis [MS] is an immune-mediated disease driven by peripherally mediated and central nervous system compartmentalized pathophysiologic processes. Major advances have led to a plethora of disease modifying therapies [DMTs] available for the treatment of MS. Among the wide range of DMTs, the immune reconstitution therapies [IRTs] are a unique subset of therapy that have the potential for durable benefit without the need for chronic administration. Cladribine tablets are a higher-efficacy oral IRT that selectively targets lymphocytes, causing a transient lymphopenia, followed by immune reconstitution of a different repertoire of lymphocytes that may result in durable benefit. The intermittent dosing schedule and efficacy in reducing measures of disease activity in both the short and long-term make cladribine an attractive DMT choice for a broad range of individuals with relapsing forms of MS. This narrative review summarizes the available efficacy and safety data from clinical trials and real-world studies on cladribine tablets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.